|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
MILAN, January 03, 2023--Newron Pharmaceuticals announces striking six-month interim results for evenamide as an add-on therapy for Treatment Resistant Schizophrenia (TRS).
MILAN, September 15, 2022--Newron Pharmaceuticals today announces its half-year 2022 financial results and operational highlights and updates its R&D and business activities.
MILAN, July 01, 2022--Newron extends Senior Management team and strengthens its commitment to ESG by appointing Filippo Moriggi as Vice President of Operations.